anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Postmarketing safety data from BOTOX Cosmetic and other approved botulinum toxins suggest that botulinum toxin effects may, in some cases, be observed beyond the site of local injection. The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death related to spread of toxin effects. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, and particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and in approved indications, symptoms consistent with spread of toxin effect have been reported at doses comparable to or lower than doses used to treat cervical dystonia and spasticity. Advise patients or caregivers to seek immediate medical care if swallowing, speech or respiratory disorders occur.

No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX/BOTOX Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines), or 100 Units (for severe primary axillary hyperhidrosis) have been reported.

No definitive serious adverse event reports of distant spread of toxin effect associated with BOTOX for blepharospasm at the recommended dose (30 Units and below), strabismus, or chronic migraine at the labeled doses have been reported.
The invention discloses a preparation method of dragon's blood and Meles meles ulcer oil. The dragon's blood and Meles meles ulcer oil is mainly prepared from dragon's blood, bee wax and Meles meles fat. The dragon's blood and Meles meles ulcer oil is used for treating various ulcers such as gastric ulcers, duodenal ulcers, colonic ulcers, burns and scalds, diabetic feet, bedsores and haemorrhoids, can be taken orally or applied externally or used in an oral taking and external applying combined mode, and is significant in treatment effect. The ulcer oil can effectively improve the body immunity, promote proliferation and migration of intradermal cells and in-vitro lumen formation, increase the blood flow of the ulcer part, regulate metabolism, induce hypodermal cells, fibrocyte, blood capillaries, nerve endings and muscles to generate a series of tissue repair, accelerate regeneration of damaged cells and ensure complete coverage of superficial cells. The ulcer oil is prepared from fatty acid extremely similar to fat of the human skin and has very strong permeability, oleic acid can form cracks by perturbing the cuticle and the lipid bilayer to promote permeation, and oleic acid and linoleic acid can promote total closure of wounds and restrain generation of nitric oxide in wound tissue. The effective rate of treatment on peptic ulcers such as gastric ulcers and intestinal ulcers reaches 99%.
After a diagnostic interview (determining the presence of MDD or an anxiety disorder) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive the nociceptin receptor antagonist. Participants will then complete an approach/avoidance task. Functional magnetic resonance imagining (fMRI) will begin 2 hours after the nociceptin receptor antagonist is administered.
Patient in lateral position, standard disinfection, puncture point selected at T7-T9 level, local anesthesia to pierce skin. Direct/lateral needle approach cautiously, confirm entry into epidural space with disappearance of resistance and negative pressure. Insert epidural catheter 3-5cm towards head, secure firmly. Test dose with 3mL 1% lidocaine injection to confirm epidural anesthesia efficacy and safety. Epidural infusion of 0.15% ropivacaine (250mL) + fentanyl (2.5mg) via patient-controlled pump at 5mL/h with bolus option. Adjust infusion rate 1-3mL/h based on pain needs.
INTRODUCTION: Small cross-sectional studies and case reports observed improvement after administration of second IVIG dose (SID) amongst Guillain-Barré Syndrome (GBS) patients not responsive to initial IVIG cycle. Nevertheless, recent clinical trial and larger observational studies did not find any positive effects of SID. Instead, an increased risk of thromboembolism and mortality was noted. The conclusions of these studies however were not robust as confounding and selection bias were present.
METHODOLOGY: Two neurologists conducted the search process (KBA and MBP) using the following terms in Medline: [(" Guillain-Barré Syndrome"[MeSH Terms] or GBS or Acute Motor Axonal Neuropathy or Acute Motor Axonal Neuropathy or Acute Inflammatory Demyelinating Polyneuropathy) AND (Poorly Responsive or Poor Prognosis or Progressive)] AND [("Intravenous Immunoglobulin"[MeSH Terms] or IVIG or IGIV) AND (second dose or retreatment or SID)].
RESULTS: Only 7 articles were included in this review. In terms of primary outcomes, although the cross-sectional study found improvement in GBS DS score at 4 weeks (Median GBS DS: 3 vs 5, p = 0.033) and the 2 case series observed improvement after SID, no significant differences between the control and intervention groups were found in the cohort [Early SIV OR: 0.7 (95% CI 0.16-3.04), Late SIV OR: 0.66 (CI: 0.18-2.5)] and clinical trial studies (Adjusted OR: 1.4 (95% CI:0.6-3.3, p = 0.45). Moreover, 4 patients who died in the clinical trial were from the intervention group.
CONCLUSION: Based on studies with research designs of higher quality, SID is not effective in the management of GBS patients who poorly responded to initial IVIG. Nevertheless, an adequately powered, randomized, double-blinded, placebo-controlled clinical trial, using GBS-DS of 3 and above after first IVIG dose should be done to effectively establish the efficacy and safety of SID as intervention for this cohort of patients.
Prior to the intravenous administration of midazolam hydrochloride in any dose, the immediate availability of oxygen, resuscitative drugs, age- and size-appropriate equipment for bag/valve/mask ventilation and intubation, and skilled personnel for the maintenance of a patent airway and support of ventilation should be ensured. Patients should be continuously monitored for early signs of hypoventilation, airway obstruction, or apnea with means readily available (e.g., pulse oximetry). Hypoventilation, airway obstruction, and apnea can lead to hypoxia and/or cardiac arrest unless effective countermeasures are taken immediately. The immediate availability of specific reversal agents (flumazenil) is highly recommended. Vital signs should continue to be monitored during the recovery period. Because intravenous midazolam can depress respiration (see CLINICAL PHARMACOLOGY), especially when used concomitantly with opioid agonists and other sedatives (see DOSAGE AND ADMINISTRATION), it should be used for sedation/anxiolysis/amnesia only in the presence of personnel skilled in early detection of hypoventilation, maintaining a patent airway, and supporting ventilation. When used for sedation/anxiolysis/amnesia, midazolam should always be titrated slowly in adult or pediatric patients. Adverse hemodynamic events have been reported in pediatric patients with cardiovascular instability; rapid intravenous administration should also be avoided in this population (see DOSAGE AND ADMINISTRATION for complete information).
This study aimed to explore the potential antiallodynic effects of rosmarinic acid, a natural antioxidant with a demonstrated safety profile across a broad dose range. Using a chronic constriction injury-induced neuropathic pain model, the impact of rosmarinic acid on allodynia was investigated. Furthermore, the involvement of adrenergic and opioidergic mechanisms in its activity was assessed. To evaluate rosmarinic acid's efficacy, doses of 10, 20, and 40 mg/kg were administered and the electronic von Frey test was utilized along with an activity cage apparatus. % MPE values were calculated to gauge the extent of pain relief. Mechanistic insights were obtained by pretreating animals with the β-adrenergic receptor antagonist propranolol, the α1-adrenergic receptor antagonist prazosin, α2-adrenergic receptor antagonist yohimbine, and the opioid receptor antagonist naloxone. Rosmarinic acid demonstrated a statistically significant antiallodynic effect that was independent of locomotor activity. This effect was noteworthy as it resembled both the level and duration of relief provided by pregabalin. Additionally, the %MPE value of the group treated with 40 mg/kg rosmarinic acid showed a significant difference compared to the value of the pregabalin-treated group (P<0.001). Pre-administration of the antagonists revealed that the antiallodynic activity was shown to be mediated by the stimulation of opioid and adrenergic receptors, with a primary contribution from α2-adrenergic receptor stimulation. Our findings suggest that rosmarinic acid may hold promise as a potential therapeutic agent for neuropathic pain. By elucidating the involvement of adrenergic and opioidergic mechanisms, we have provided valuable preclinical data that could inform novel treatment approaches.
A pharmaceutical product which contains, live, viable embryo cells of mammals in a liquid or solid inert medium is described. These products are produced by removing the uterus of a pregnant mammal, for example after half the usual gestation period of the species to three-quarters of the usual gestation period of the species, and removing the fetus or the fetuses from the uterus under aseptic conditions. The fetuses are dissected, the individual tissues, organs and glands are freed of adherent tissue fibres and body fluids and subsequently reduced to small pieces which are then mechanically disrupted to individual cells. These individual cells are dispersed in an inert liquid medium and the product is deep-frozen where appropriate. Damaged adult mammalian cells mixed with the live, viable embryo cells in a cell culture show a distinct growth and/or a distinct restoration of the disturbed morphology. It is possible in a test method to detect cell-regenerating factors in the serum of adult mammals by mixing this serum with adult damaged mammalian cells, in which case a distinct growth or a restoration of the disturbed morphology indicates the presence of cell-regenerating components in the serum here too.
As with all therapeutic proteins, there is a potential for immunogenicity. The development of anti-ANTHIM antibodies was evaluated in all subjects receiving single and double doses of ANTHIM in studies 1, 2 and 3. Eight subjects (2.5%) who received at least one dose of IV ANTHIM were positive for a treatment-emergent anti-therapeutic antibody (ATA) response. Quantitative titers were low ranging from 1:20 – 1:320. There was no evidence of altered PK or toxicity profile in subjects with ATA development.

The incidence of antibody formation is highly dependent on the sensitivity and specificity of the immunogenicity assay. Additionally, the observed incidence of any antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to obiltoxaximab with the incidence of antibodies to other products may be misleading.
OXYGEN COMPRESSED U.S.P. UN 1072 Oxygen produced by air liquefaction Warning: Oxidizing gas which vigorously accelerates combustion. Handle and store with care. Do not drop. Keep upright. Do not use or store near heat or flame. Keep free from oil or grease. Use only with equipment designed, cleaned and rated for use with medical oxygen systems. Open valve slowly. Close valve after each use and when empty. Uninterrupted use of high concentrations of oxygen over an extended period of time without monitoring its effects may be harmful. Do not attempt to use on patients who have stopped breathing, unless used in conjunction with resuscitative equipment.  
  
Filled by: ENOS HOME OXYGEN AND MEDICAL SUPPLY, INC.   
35 Welby Road New Bedford, MA 02745   
508-992-2146 1-800-473-4669
Disclosed is a multilayer skin equivalent having (i) a scaffold layer incorporated with dermis-forming cells, and (ii) a keratinocyte layer. Also disclosed is a multilayer dermal equivalent having at least one of (i) a first layer of at least one skin-associated extracellular matrix component containing papillary dermal fibroblasts; and, in laminar relationship therewith, (ii) a second layer of at least one skin-associated extracellular matrix component containing reticular dermal fibroblasts. Preferred embodiments include those where the scaffold or dermis-forming layer is a multilayer selected from the group consisting of (a) a layer containing isolated papillary dermis-forming cells and a layer containing isolated reticular dermis-forming cells; (b) a layer containing isolated papillary dermis-forming cells and a layer containing isolated, culture expanded mesenchymal stem cells; and (c) a layer containing isolated reticular dermisforming cells and a layer containing isolated, culture expanded mesenchymal stem cells. Also enclosed is a multilayer skin equivalent having (i) a scaffold layer comprising a first layer of at least one skin-associated extracellular matrix component containing papillary dermal fibroblasts and, in laminar relationship therewith, a second layer of at least one skin-associated extracellular matrix component containing reticular dermal fibroblasts; and (ii) a keratinocyte layer. Also disclosed is an injectable composition of dermis-forming cells and at least one skin-associated extracellular matrix component in a pharmaceutically acceptable injectable carrier. The injectable composition can further include keratinocytes.
Lung cancer is the most common and lethal malignancy, with lung adenocarcinoma accounting for approximately 40% of all cases. Despite some progress in understanding the pathogenesis of this disease and developing new therapeutic approaches, the current treatments for lung adenocarcinoma remain ineffective due to factors such as high tumour heterogeneity and drug resistance. Therefore, there is an urgent need to identify novel therapeutic targets. Calcyclin-binding protein (CacyBP) can regulate a variety of physiological processes by binding to different proteins, but its function in lung adenocarcinoma is unknown. Here, we show that CacyBP is highly expressed in lung adenocarcinoma tissues, and high CacyBP expression correlates with poorer patient survival. Moreover, overexpression of CacyBP promoted the proliferation, migration and invasion of lung adenocarcinoma cell lines. Further mechanistic studies revealed that CacyBP interacts with the tumour suppressor ovarian tumour (OTU) deubiquitinase 5 (OTUD5), enhances the ubiquitination and proteasomal degradation of OTUD5 and regulates tumourigenesis via OTUD5. In conclusion, our study reveals a novel mechanism by which CacyBP promotes tumourigenesis by increasing the ubiquitination level and proteasome-dependent degradation of OTUD5, providing a potential target for the treatment of lung adenocarcinoma.
BACKGROUND: Variability in biological parameters may be associated with adverse outcomes. The aim of the study was to determine whether variability in body mass index (BMI) and blood pressure is associated with all-cause, cardiovascular mortality and cancer mortality or with renal disease progression in subjects with type 2 diabetes.
METHODS: The diabetes database was accessed, and all the information on patient visits (consultations) carried out in the study period (1 January 2008-31 December 2019) was extracted and linked to the laboratory database and the mortality register.
RESULTS: The total number of patients included in the study population was 26,261, of whom 54.4% were male. Median (interquartile range, IQR) age was 60.2 (51.8-68.3) years. The coefficient of variability of BMI was independently associated with increased all-cause and cardiovascular, but not cancer, mortality. Glycated haemoglobin (HbA1c) was associated with increased all-cause, cardiovascular, and cancer mortality as well as with renal progression. Variability in systolic blood pressure, diastolic blood pressure, and pulse pressure was associated with increased all-cause and cardiovascular mortality in bivariate, but not in multivariate, analyses.
CONCLUSIONS: Variability in BMI was associated with increased all-cause and cardiovascular, but not cancer, mortality in a large real-world contemporary population. Our results also confirm the association of HbA1c with increased all-cause, cardiovascular, and cancer mortality as well as with renal progression.
PURPOSE: To improve the strength of a calcium granule and to obtain the granule which is difficult to crush and easy to replace and absorb when filled in the bone by incorporating the porous granule consisting of the aggregated grain of α-tricalcium phosphate. CONSTITUTION: Citric acid and disodium hydrogen phosphate are added to purified water as a buffer, carboxymethyl cellulose is added as a thickener, and the mixture is agitated and dissolved to obtain a processing soln. at pH 3-8. The porous granule of α-tricalcium phosphate of Ca3 (PO4 )2 having 50-2500μm grain diameter, 0.5-50μm pore diameter and >=50MPa compressive strength is added in several portions to the processing soln. to control the weight ratio of the α-tricalcium phosphate powder to processing soln. and kneaded, the kneaded material is calcined at 1250-1700 deg.C for 3hr and then cooled from 1250 to 850 deg.C at the rate of -4 deg.C/min to 30 deg.C/min, then the calcined material is crushed, and the granule of the desired diameter is obtained by using several kinds of screens. The granule is sterilized with hot air to obtain a calcium granule.
FIELD: medicine, pharmacology, pharmacy. SUBSTANCE: invention relates to vitamin-mineral complexes designated for prophylaxis and treatment. Vitamin-mineral complex is prepared of three-five preparative forms of different composite designated for separate intake. Each of such forms comprises vitamins and mineral substances that are compatible with respect to their assimilation and storage. Invention provides minimization of intake doses of vitamins and mineral substances in their satisfactory requirement of human body, in suitable use of complexes, decrease of labor intensity in their production and increase of time storage. EFFECT: improved valuable properties and indices. 15 cl
<P>PROBLEM TO BE SOLVED: To obtain a cancer metastasis suppressing agent containing an enzyme-treated preparation of Agaricus blazei (ABPC: Agaricus Blazei Practical Compound).  <P>SOLUTION: This cancer metastasis suppressing agent contains Agaricus blazei. As another embodiment, an enzyme-treated preparation of Agaricus blazei is used as a component of the cancer metastasis suppressing agent. The present invention provides the cancer metastasis suppressing agent containing Agaricus blazei. Agaricus blazei is useful for suppressing the metastasis of cancer.  <P>COPYRIGHT: (C)2004,JPO
A robotic bending apparatus for bending archwires and other types of elongate, bendable medical devices into a desired configuration includes a first gripping tool and a moveable gripping tool. The first gripping tool can be either fixed with respect to a base or table for the robot or positioned at the end of robot arm. The moveable gripping tool is mounted to the end of a moveable robot arm having a proximal portion also mounted to the base. The robot preferably comprises a six axis bending robot, in which the distal end of the moveable arm can move relative to the fixed gripping tool about three translational axes and three rotational axes. The gripping tools preferably incorporate force sensors which are used to determine overbends needed to get the desired final shape of the archwire. The robot may also include a resistive heating system in which current flows through the wire while the wire is held in a bent condition to heat the wire and thereby retain the bent shape of the wire. A magazine for holding a plurality of straight archwires needing to be bent and a conveyor system for receiving the wires after the bending process is complete are also described. The robot bending system is able to form archwires with any required second and third order bends quickly and with high precision. As such, it is highly suitable for use in a precision appliance-manufacturing center manufacturing a large number of archwires (or other medical devices or appliances) for a distributed base of clinics.
BACKGROUND: The aim of the study was to compare the short-term outcome of SuperPATH, direct anterior (DAA) and conventional approach (CA) hemiarthroplasty (HA) in patients with femoral neck fractures using a network meta-analysis.
METHODS: PubMed, China National Knowledge Infrastructure, Epistemonikos, and Embase were searched until May 31, 2024. In a network meta-analysis, mean differences with 95% confidence intervals were calculated using the Hartung-Knapp-Sidik-Jonkman method and a fixed/random effects model for continuous outcomes, and odds ratios with 95% confidence intervals were calculated using the Mantel-Haenszel method and a fixed/random effects model for dichotomous outcomes.
RESULTS: The literature search identified a total of 9 randomized controlled trials on SuperPATH with 762 patients and 8 randomized controlled trials on DAA with 641 patients. In the overall ranking, SuperPATH was placed first, DAA second and CA third. SuperPATH HA was best in 7, second best in 2 and third best in 1 of the 10 outcome parameters. DAA HA was best in 2 and second best in 8 of the 10 outcome parameters. CA HA was best in 1 and third best in 9 of the 10 outcome parameters. In the indirect comparison between SuperPATH HA and DAA HA, SuperPATH HA had a 1.36 point lower visual analog scale at 2 to 7 days postoperatively and a 0.17 lower overall complication rate compared to DAA.
CONCLUSION: For the treatment of patients with femoral neck fractures, SuperPATH HA ranked first, DAA HA ranked second and CA HA ranked third. Based on the results, we recommend that trauma surgeons increase their use of minimally invasive hip HA techniques. It should be noted that SuperPATH HA had a significantly lower overall complication rate compared to DAA HA when the minimally invasive technique was chosen.
BACKGROUND: Kinematic analysis has been recommended to quantify the upper limb motor function after stroke. However, previous studies have rarely reported the kinematic data of the post-stroke patients with moderate to severe upper limb paresis due to the poor accomplishment of the complex tasks.
METHODS: 27 post-stroke individuals and 20 non-disabled people participated in the study. The trunk and upper limb movements during the Hand-to-mouth task were captured by the motion capture system and upper extremity kinematic analysis software automatically. The subgroup analysis within stroke group were conducted layering by the Fugl-Meyer Assessment for Upper Extremity scores (severe: 16-31; moderate: 32-50).
FINDINGS: The paretic upper limbs in the stroke group tended to use more trunk and shoulder compensatory strategies to offset the impact of spasticity and weakness compared with non-disabled controls. The less-affected limbs in the stroke group also showed abnormal kinematic data. There were significant differences between the kinematic metrics of severe and moderate subgroups.
INTERPRETATION: The Hand-to-mouth task is a good and feasible option for kinematic analysis of these patients. It is essential to layer the severity of the paresis and put more emphasis on trunk movements in the future kinematic studies.